PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Miniature ‘plug-and-play’ platform could accelerate development of new PET tracers
Researchers are developing a system that combines a universal radioactive building block with different biological molecules to create new radiotracers.
FDA clears AI platform for PET imaging enhancement and quantification
The software supports amyloid, tau and FDG PET and provides automated Centiloid measurements for amyloid imaging and CenTauR measurements for tau imaging.
Physician groups launch national alliance to protect PET imaging access
The launch comes ahead of meetings with members of Congress this fall in Washington, D.C., where group leaders plan to advocate for the availability of cardiac PET, particularly among underserved populations.
Siemens Healthineers invests nearly $44M to boost PET/CT production
The finalized project was designed to increase production capacity and support growing demand for PET/CT technology, including new product lines planned for the United States and international markets.
Bayer's investigational PET tracer shows high accuracy for cardiac amyloidosis
The imaging agent could offer a new approach for diagnosing stiff heart syndrome, according to data presented during the European Society of Cardiology Congress.

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

Largest network of private cardiology groups in US to deploy GE HealthCare's cardiac PET tracer

One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.

Some PET exams may be overutilized in oncology

In 2020 alone, there were more than 2 million 18F-FDG PET/CT scans conducted in the United States.

PSMA-PET imaging not the most cost-effective option for many prostate cancer patients

The exam effectively helps providers manage patients’ treatment options, but for some, the costs associated with those treatments may negate the value of its findings.

PET study targets inflammation to predict AMI recovery

Inflammation-targeting PET method predicts recovery after heart attack

Targeting CXCR4 during PET scans could help providers gain vital information regarding patients' potential to fully recover from myocardial infarction.

Nuclear cardiology is entering a new era—one that goes well beyond the traditional focus on myocardial perfusion imaging. According to Marcelo Di Carli, MD, editor-in-chief of the Journal of Nuclear Cardiology and chief of the Division of Nuclear Medicine at Brigham and Women’s Hospital, the field is rapidly expanding into diagnosing and monitoring complex cardiac diseases such as amyloidosis, sarcoidosis, myocarditis, and cardiac infections.

Nuclear cardiology expands beyond perfusion imaging as it enters a new era

Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.

Positron emission tomography (PET) nuclear imaging has seen rapid expansion in cardiology and oncology due to its improve accuracy over SPECT and its ability to expand into new areas of cardiovascular imaging. A new review in the American Heart Association journal Stroke outlines another possible use of PET to assess carotid artery atherosclerosis for stroke prevention. Figure courtesy Stroke, https://www.ahajournals.org/doi/10.1161/STROKEAHA.125.050399

PET holds promise for carotid plaque assessments

PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.

Imaging offers insight into impact of new Alzheimer's treatment from Eli Lilly

Emerging research provides further evidence that amyloid-removal treatment for Alzheimer’s effectively slows cognitive decline.

obesity semaglutide tirzepatide GLP-1 drugs weight loss

GLP-1 receptor agonists alter glucose metabolism and the movement of food through the digestive system and can lead to unique uptake patterns on FDG PET-CT.

PET/CT

Miniature ‘plug-and-play’ platform could accelerate development of new PET tracers

FDA clears AI platform for PET imaging enhancement and quantification

Physician groups launch national alliance to protect PET imaging access

Siemens Healthineers invests nearly $44M to boost PET/CT production

Bayer's investigational PET tracer shows high accuracy for cardiac amyloidosis